MedTrace Logo

Disease Control in RRMS Transferring Treatment From Natalizumab to Fingolimod

NCT02277964 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2016-09-14

No results posted yet for this study

Summary

This is an observational study to develop new hypothesis regarding the dynamic and safety of switching from natalizumab to fingolimod:

* Comparison of disease activity (clinical and MRI) during the year after change of therapy in comparison to the year before change
* Dynamic of onset of disease activity after having stopped treatment with natalizumab
* Change of immunological parameters during treatment change from natalizumab to fingolimod in comparison to clinical and MRI measures

Conditions

  • Relapsing Remitting Multiple Sclerosis

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • University Hospital, Basel, Switzerland

    lead OTHER

Principal Investigators

  • Ludwig Kappos, Prof., MD · Department of Neurology, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2016-08-31
Completion
2016-08-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02277964 on ClinicalTrials.gov